Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

BACKGROUND: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. METHODS: Bevacizumab was administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, P, Decio, A, Castiglioni, V, Bassi, A, Pesenti, E, Cesca, M, Scanziani, E, Belotti, D, Giavazzi, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394985/
https://www.ncbi.nlm.nih.gov/pubmed/22713663
http://dx.doi.org/10.1038/bjc.2012.261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394985/
https://www.ncbi.nlm.nih.gov/pubmed/22713663
http://dx.doi.org/10.1038/bjc.2012.261

Ejemplares similares